Open-Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy.
4RTNI
PSPRS
progressive supranuclear palsy (PSP)
salsalate
young plasma
Journal
Movement disorders clinical practice
ISSN: 2330-1619
Titre abrégé: Mov Disord Clin Pract
Pays: United States
ID NLM: 101630279
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
14
01
2020
revised:
18
02
2020
accepted:
26
02
2020
entrez:
7
5
2020
pubmed:
7
5
2020
medline:
7
5
2020
Statut:
epublish
Résumé
Progressive supranuclear palsy (PSP) is a neurodegenerative disease without approved therapies, and therapeutics are often tried off-label in the hope of slowing disease progression. Results from these experiences are seldom shared, which limits evidence-based knowledge to guide future treatment decisions. To describe an open-label experience, including safety/tolerability, and longitudinal changes in biomarkers of disease progression in PSP-Richardson's syndrome (PSP-RS) patients treated with either salsalate or young plasma and compare to natural history data from previous multicenter studies. For 6 months, 10 PSP-RS patients received daily salsalate 2,250 mg, and 5 patients received monthly infusions of four units of young plasma. Every 3 months, clinical severity was assessed with the Progressive Supranuclear Palsy Rating Scale (PSPRS), and MRI was obtained for volumetric measurement of midbrain. A range of exploratory biomarkers, including cerebrospinal fluid levels of neurofilament light chain, were collected at baseline and 6 months. Interventional data were compared to historical PSP-RS patients from the davunetide clinical trial and the 4-Repeat Tauopathy Neuroimaging Initiative. Salsalate and young plasma were safe and well tolerated. PSPRS change from baseline (mean ± standard deviation [SD]) was similar in salsalate (+5.6 ± 9.6), young plasma (+5.0 ± 7.1), and historical controls (+5.6 ± 7.1), and change in midbrain volume (cm Neither salsalate nor young plasma had a detectable effect on disease progression in PSP-RS. Focused open-label clinical trials incorporating historical clinical, neuropsychological, fluid, and imaging biomarkers provide useful preliminary data about the promise of novel PSP-directed therapies.
Sections du résumé
BACKGROUND
BACKGROUND
Progressive supranuclear palsy (PSP) is a neurodegenerative disease without approved therapies, and therapeutics are often tried off-label in the hope of slowing disease progression. Results from these experiences are seldom shared, which limits evidence-based knowledge to guide future treatment decisions.
OBJECTIVES
OBJECTIVE
To describe an open-label experience, including safety/tolerability, and longitudinal changes in biomarkers of disease progression in PSP-Richardson's syndrome (PSP-RS) patients treated with either salsalate or young plasma and compare to natural history data from previous multicenter studies.
METHODS
METHODS
For 6 months, 10 PSP-RS patients received daily salsalate 2,250 mg, and 5 patients received monthly infusions of four units of young plasma. Every 3 months, clinical severity was assessed with the Progressive Supranuclear Palsy Rating Scale (PSPRS), and MRI was obtained for volumetric measurement of midbrain. A range of exploratory biomarkers, including cerebrospinal fluid levels of neurofilament light chain, were collected at baseline and 6 months. Interventional data were compared to historical PSP-RS patients from the davunetide clinical trial and the 4-Repeat Tauopathy Neuroimaging Initiative.
RESULTS
RESULTS
Salsalate and young plasma were safe and well tolerated. PSPRS change from baseline (mean ± standard deviation [SD]) was similar in salsalate (+5.6 ± 9.6), young plasma (+5.0 ± 7.1), and historical controls (+5.6 ± 7.1), and change in midbrain volume (cm
CONCLUSIONS
CONCLUSIONS
Neither salsalate nor young plasma had a detectable effect on disease progression in PSP-RS. Focused open-label clinical trials incorporating historical clinical, neuropsychological, fluid, and imaging biomarkers provide useful preliminary data about the promise of novel PSP-directed therapies.
Identifiants
pubmed: 32373661
doi: 10.1002/mdc3.12940
pii: MDC312940
pmc: PMC7197321
doi:
Types de publication
Journal Article
Langues
eng
Pagination
440-447Subventions
Organisme : NIA NIH HHS
ID : K23 AG059888
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002369
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG038791
Pays : United States
Organisme : NIA NIH HHS
ID : T32 AG023481
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062422
Pays : United States
Informations de copyright
© 2020 International Parkinson and Movement Disorder Society.
Références
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
Lancet Neurol. 2019 Jun;18(6):549-558
pubmed: 31122495
Alzheimers Dement (Amst). 2018 Sep 12;10:563-572
pubmed: 30406175
Neurology. 2018 Jan 23;90(4):e273-e281
pubmed: 29282336
Mov Disord. 2014 Apr;29(4):470-8
pubmed: 24532007
Ann Clin Transl Neurol. 2018 Sep 20;5(10):1250-1263
pubmed: 30349860
JAMA Neurol. 2019 Jan 1;76(1):35-40
pubmed: 30383097
Neuron. 2010 Sep 23;67(6):953-66
pubmed: 20869593
JAMA Neurol. 2016 Nov 1;73(11):1325-1333
pubmed: 27598869
J Clin Exp Neuropsychol. 1998 Jun;20(3):310-9
pubmed: 9845158
Lancet Neurol. 2014 Jul;13(7):676-85
pubmed: 24873720
Neuroimage. 2007 Oct 15;38(1):95-113
pubmed: 17761438
Science. 2014 May 9;344(6184):630-4
pubmed: 24797482
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Brain. 2007 Jun;130(Pt 6):1552-65
pubmed: 17405767
Neurol Neuroimmunol Neuroinflamm. 2016 Aug 02;3(5):e266
pubmed: 27583276
Neurology. 2016 Nov 8;87(19):2016-2025
pubmed: 27742814
Nat Med. 2014 Jun;20(6):659-63
pubmed: 24793238
JAMA Neurol. 2019 Dec 20;:
pubmed: 31860007
Lancet Neurol. 2017 Jul;16(7):552-563
pubmed: 28653647
Parkinsonism Relat Disord. 2016 Jul;28:41-48
pubmed: 27172829
Front Neurosci. 2012 Dec 05;6:171
pubmed: 23227001
J Psychiatr Res. 1982-1983;17(1):37-49
pubmed: 7183759
Nat Med. 2015 Oct;21(10):1154-62
pubmed: 26390242
J Clin Exp Neuropsychol. 2019 Jul;41(5):469-475
pubmed: 30712468
Neuroimage. 2005 Jul 1;26(3):839-51
pubmed: 15955494
Neurology. 2016 May 3;86(18):1736-43
pubmed: 27037234
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
JAMA Neurol. 2019 Nov 11;:
pubmed: 31710340